ClinicalTrials.gg
CompletedNCT04535999Updated Oct 30, 2026Results posted

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

A Phase 4 interventional study of Secukinumab Auto-Injector in Psoriasis, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
49th of 54
16 · median 124
Started
2022
the only one that year
Phase 4
17 of 54
4 open now
Registered
46th of 54
by date

Among the 54 studies testing secukinumab in Psoriasis, this one is the 49th largest by enrollment, is the only one that started in 2022, is one of 17 in phase 4, and was the 46th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

Read the detailed description

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to response and different methods of defining nail disease response.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI>20
  • Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist
  • Age 18-85

Exclusion criteria

Exclusion Criteria:

  • History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable)
  • Inflammatory bowel disease
  • Metal implants or other concerns for use of MRI
  • Active infection
  • Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening.
  • We will exclude patients with onychomyosis of the fingernails on clippings
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Open Label

    Secukinumab

    Drug: Secukinumab Auto-Injector

Interventions

  • DrugSecukinumabStudies of SecukinumabSecukinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)

    Also known as: Cosentyx

06

What researchers measure

Primary outcomes

  1. Change in NAPSI

    Nail Psoriasis Severity Index (NAPSI): NAPSI is the most comprehensive nail assessment used in clinical trials. The fingernail is divided into four quadrants. For each quadrant, 1 point is assigned for a nail matrix abnormality and 1 point for a nail bed abnormality allowing for a total of 8 points per nail. 0-80 total points possible with a higher score corresponding to a worse outcome.

    Time frame: 24 Weeks

Secondary outcomes

  1. Change in mNAPSI

    modified Nail Psoriasis Severity Index (mNAPSI): A modified version of the primary outcome measure, the mNAPSI includes more features of nail disease. It has previously demonstrated greater correlation with the physician global assessment, assessing the nail as a whole rather than quadrants with improved reliability and responsiveness. 0-130 total points possible with a higher score corresponding to a worse outcome.

    Time frame: 24 Weeks

  2. Change in Physician Global Assessment of Nail Disease

    Physician Global Assessment of Nail Disease. Scale of 0-100 with higher score corresponding to a worse outcome (0=clear, 100=very severe).

    Time frame: 24 Weeks

  3. Change in Patient Global Assessment of Nail Disease

    Patient Global Assessment of Nail Disease. Scale of 0-10 with higher score corresponding to a worse outcome (0=excellent, 10=poor).

    Time frame: 24 Weeks

  4. Change in PASI

    Psoriasis Area Severity Index (PASI): Four assessments for each of four body areas (head, trunk, upper extremities, and lower extremities) are provided. The assessments are erythema, induration, and scale (each assessed as 0-4 using a standardized scale), and the number of palms/percentage of each area is categorized (0 = 0%, 1 = less than 10%, 2 = 10%-29%, 3 = 30%-40%, 4 = 50%-69%, Scale of 0 to 72 with a higher score corresponding to a worse outcome.

    Time frame: 24 Weeks

  5. Change in DLQI

    Dermatology Life Quality Index (DLQI): There are a total of 10 questions and each question is scored on a four-point Likert scale: Very much = 3 A lot = 2 A little = 1 Not at all = 0 Not relevant = 0 Question unanswered = 0 The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.

    Time frame: 24 Weeks

  6. Change in NAPPA

    Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Patient-reported outcome designed to emphasize quality of life, patient-related needs, and treatment benefit. The NAPPA captures domains such as pain, function, cosmetic, and psychosocial burden. The NAPPA QoL contains 20 questions, each scored on a five-point Likert scale: 0 = not at all 1. = somewhat 2. = moderately 3. = quite a bit 5 = very The score is calculated by adding the score of each question, resulting in a maximum of 100 and a minimum of 0. Higher score indicates greater impact of disease.

    Time frame: 24 Weeks

07

Results

Posted Oct 30, 2026
Limitations and caveats
Study limitations included single center setting and small sample size due to recruitment and retention barriers.

Participant flow

Participant flow — Overall Study
MilestoneOpen Label
Started16
Completed10
Not completed6

Outcome measures

PrimaryChange in NAPSI

Nail Psoriasis Severity Index (NAPSI): NAPSI is the most comprehensive nail assessment used in clinical trials. The fingernail is divided into four quadrants. For each quadrant, 1 point is assigned for a nail matrix abnormality and 1 point for a nail bed abnormality allowing for a total of 8 points per nail. 0-80 total points possible with a higher score corresponding to a worse outcome.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in NAPSI
score on a scaleOpen Label
Change in NAPSI-23.7 ± 14.3
SecondaryChange in mNAPSI

modified Nail Psoriasis Severity Index (mNAPSI): A modified version of the primary outcome measure, the mNAPSI includes more features of nail disease. It has previously demonstrated greater correlation with the physician global assessment, assessing the nail as a whole rather than quadrants with improved reliability and responsiveness. 0-130 total points possible with a higher score corresponding to a worse outcome.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in mNAPSI
score on a scaleOpen Label
Change in mNAPSI-20.2 ± 14.2
SecondaryChange in Physician Global Assessment of Nail Disease

Physician Global Assessment of Nail Disease. Scale of 0-100 with higher score corresponding to a worse outcome (0=clear, 100=very severe).

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in Physician Global Assessment of Nail Disease
score on a scaleOpen Label
Change in Physician Global Assessment of Nail Disease-36.5 ± 11.4
SecondaryChange in Patient Global Assessment of Nail Disease

Patient Global Assessment of Nail Disease. Scale of 0-10 with higher score corresponding to a worse outcome (0=excellent, 10=poor).

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in Patient Global Assessment of Nail Disease
score on a scaleOpen Label
Change in Patient Global Assessment of Nail Disease-2.2 ± 3.1
SecondaryChange in PASI

Psoriasis Area Severity Index (PASI): Four assessments for each of four body areas (head, trunk, upper extremities, and lower extremities) are provided. The assessments are erythema, induration, and scale (each assessed as 0-4 using a standardized scale), and the number of palms/percentage of each area is categorized (0 = 0%, 1 = less than 10%, 2 = 10%-29%, 3 = 30%-40%, 4 = 50%-69%, Scale of 0 to 72 with a higher score corresponding to a worse outcome.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in PASI
score on a scaleOpen Label
Change in PASI-3.1 ± 2.7
SecondaryChange in DLQI

Dermatology Life Quality Index (DLQI): There are a total of 10 questions and each question is scored on a four-point Likert scale: Very much = 3 A lot = 2 A little = 1 Not at all = 0 Not relevant = 0 Question unanswered = 0 The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in DLQI
score on a scaleOpen Label
Change in DLQI-8.1 ± 7.1
SecondaryChange in NAPPA

Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Patient-reported outcome designed to emphasize quality of life, patient-related needs, and treatment benefit. The NAPPA captures domains such as pain, function, cosmetic, and psychosocial burden. The NAPPA QoL contains 20 questions, each scored on a five-point Likert scale: 0 = not at all 1. = somewhat 2. = moderately 3. = quite a bit 5 = very The score is calculated by adding the score of each question, resulting in a maximum of 100 and a minimum of 0. Higher score indicates greater impact of disease.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Change in NAPPA
score on a scaleOpen Label
Change in NAPPA-20.7 ± 17.9

Adverse events

Collected over Baseline to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open Label
Mean48.4 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Open Label
Female5
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
PASI
PASI(score on a scale)Open Label
Mean3.9 ± 2.9
NAPSI
NAPSI(score on a scale)Open Label
Mean33.9 ± 16.3
mNAPSI
mNAPSI(score on a scale)Open Label
Mean25.8 ± 16.5
Physician Nail Global Assessment
Physician Nail Global Assessment(score on a scale)Open Label
Mean56 ± 13.6
Patient Nail Global Assessment
Patient Nail Global Assessment(score on a scale)Open Label
Mean4.8 ± 2.4

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Hospital at the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in May 2025, 39 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 39 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 2, 2020
StartActual
Feb 7, 2022
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in NAPSITime frame: Baseline to 24 Weeks → 24 Weeks
Oct 30, 2026
Documents
Secondary outcomes
3 edited, 3 added
What changed in the outcomes
  • EditedChange in PASITime frame: Baseline to 24 Weeks → 24 Weeks
  • EditedChange in Physician Global Assessment of Nail DiseaseTime frame: Baseline to 24 Weeks → 24 Weeks
  • EditedChange in DLQITime frame: Baseline to 24 Weeks → 24 Weeks
  • AddedChange in mNAPSITime frame: 24 Weeks
  • AddedChange in Patient Global Assessment of Nail DiseaseTime frame: 24 Weeks
  • AddedChange in NAPPATime frame: 24 Weeks
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in NAPSITime frame: Baseline to 24 Weeks → 24 Weeks
    Secondary outcomes 3 edited, 3 added
    What changed in the outcomes
    • EditedChange in PASITime frame: Baseline to 24 Weeks → 24 Weeks
    • EditedChange in Physician Global Assessment of Nail DiseaseTime frame: Baseline to 24 Weeks → 24 Weeks
    • EditedChange in DLQITime frame: Baseline to 24 Weeks → 24 Weeks
    • AddedChange in mNAPSITime frame: 24 Weeks
    • AddedChange in Patient Global Assessment of Nail DiseaseTime frame: 24 Weeks
    • AddedChange in NAPPATime frame: 24 Weeks
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04535999
Collaborators
Novartis
Responsible party
Sponsor
First posted
Sep 2, 2020
Start date
Feb 7, 2022
Primary completion
May 30, 2025
Completion
May 30, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Alexis Ogdie-Beatty, MD
principal investigator · University of Pennsylvania

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion